logo
  • About Us
    • Corporate Profile
    • Management Team
    • Milestones
    • Our Vision
    • Affiliates
      • CTTQ Akesobio
      • Akeso Pharma
      • AD Pharmaceuticals
    • Contact Us
  • R&D and science
    • Technology Platform
    • Products Center
    • R&D and Manufacturing
    • Expanded Access Policy
  • Collaborations
  • Investor Relations
    • Financial Reports
    • Presentations
    • IR Monthly Reports
    • Announcements and Circulars
    • Corporate Governance
    • IR Calendar
    • IR Contact
  • Media
    • Akeso News
    • Media Coverage
  • Career
    • Social Recruitment
    • Campus Recruitment
  • Privacy Policy
简 | EN |
Ivonescimab Receives NMPA Priority Review for First-Line Biliary Tract Cancer
2026-11-05
Ivonescimab Receives NMPA Priority Review for First-Line Biliary Tract Cancer
Phase II Study of Ivonescimab in the Perioperative Setting for Resectable NSCLC Published in Nature Medicine
2026-11-05
Phase II Study of Ivonescimab in the Perioperative Setting for Resectable NSCLC Published in Nature Medicine
Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented at the ESMO 2026 Presidential Symposium
2026-10-25
Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented at the ESMO 2026 Presidential Symposium
Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to evalsuate Ivonescimab in First-Line Biliary Tract Cancer
2026-10-21
Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to evalsuate Ivonescimab in First-Line Biliary Tract Cancer
Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab
2026-10-19
Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab
First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer
2026-10-10
First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer
First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer
2026-09-28
First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer
Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026
2026-09-22
Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026
Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC
2026-09-03
Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC
Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
2026-08-28
Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer: HARMONi-GI1 Meets Primary Endpoint
2026-08-26
Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer: HARMONi-GI1 Meets Primary Endpoint
Akeso's AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline
2026-08-21
Akeso's AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline
1 2 3 4 5 6 7 8 9 »
  • About Us
    • Corporate Profile
    • Management Team
    • Milestones
    • Our Vision
    • Affiliates
      • CTTQ Akesobio
      • Akeso Pharma
      • AD Pharmaceuticals
    • Contact Us
  • R&D and science
    • Technology Platform
    • Products Center
    • R&D and Manufacturing
    • Expanded Access Policy
  • Collaborations
  • Investor Relations
    • Financial Reports
    • Presentations
    • IR Monthly Reports
    • Announcements and Circulars
    • Corporate Governance
    • IR Calendar
    • IR Contact
  • Media
    • Akeso News
    • Media Coverage
  • Career
    • Social Recruitment
    • Campus Recruitment
  • Privacy Policy
WeChat
qr

Feedback ?

Tell us what you think about our

company, products, or website

COPYRIGHT | PRIVATE | Copyright © 2012-2025 Akeso Biopharma Co., Ltd. | 粤ICP备49945910 |  Developed by Euroland IR